Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.76 |
| ▸ | AXL | P30530 | 7/20 | 0.76 |
| ▸ | KDR | P35968 | 7/20 | 0.76 |
| ▸ | RET | P07949 | 3/20 | 0.68 |
| ▸ | KIT | P10721 | 3/20 | 0.68 |
| ▸ | FLT3 | P36888 | 3/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.68 |
| ▸ | MERTK | Q12866 | 5/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.67 |
| ▸ | FLT1 | P17948 | 3/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.64 |
| ▸ | AURKA | O14965 | 2/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469345 | 0.99 | MET (0.75) | METAXLKDRRETKIT | |
| SCHEMBL469254 | 0.95 | MET (0.68) | METAXLKDRRETKIT | |
| SCHEMBL21941631 | 0.95 | MET (0.68) | METAXLKDRRETKIT | |
| SCHEMBL469279 | 0.95 | MET (0.68) | METAXLKDRRETKIT | |
| SCHEMBL469261 | 0.94 | MET (0.67) | METAXLKDRRETKIT | |
| SCHEMBL469281 | 0.94 | MET (0.67) | METAXLKDRRETKIT | |
| SCHEMBL469398 | 0.94 | MET (0.73) | METAXLKDRRETKIT | |
| SCHEMBL5045440 | 0.94 | MET (0.73) | METAXLKDRRETKIT | |
| SCHEMBL469399 | 0.93 | MET (0.72) | METAXLKDRRETKIT | |
| SCHEMBL469286 | 0.93 | MET (0.72) | METAXLKDRRETKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4279138-A2 | CRYSTAL OF COMPOUND AS C-MET KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230263795-A1 | COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY | Tianjin Medical University Cancer Institute and Hospital (CN) | 2023-08-24 | — | — | US | disclosed |
| WO-2022268158-A1 | USE OF COMPOUND AS C-MET KINASE INHIBITOR FOR TREATMENT OF NEUROFIBROMATOSIS TYPE I | 正大天晴药业集团股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20210047272-A1 | CRYSTALLINE OF COMPOUND AS C-MET KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| EP-3766870-A1 | CRYSTAL OF COMPOUND AS C-MET KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-8664244-B2 | Compounds as c-Met kinase inhibitors | Advenchen Pharmaceuticals, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120123126-A1 | Compounds As c-Met Kinase Inhibitors | CHEN GUOQING PAUL (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2012034055-A2 | COMPOUNDS AS C-MET KINASE INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123126-A1 | Compounds As c-Met Kinase Inhibitors | MET, MERTK, HGF | MET 1/4885AXL 75/4885KDR 22/4885 |
| US-20210047272-A1 | CRYSTALLINE OF COMPOUND AS C-MET KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | MET, FLT1, WEE2 | MET 1/4885AXL 53/4885KDR 10/4885 |
| US-20230263795-A1 | COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY | MET, PDCD1LG2, PDCD1 | MET 1/4885AXL 137/4885KDR 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.